A global alternative asset manager based in China focuses on investments in the healthcare sector, providing equity and/or mezzanine capital to early and growth-stage companies. The firm has raised four funds to date and is making new investments from its fourth 2014 vintage fund. Depending on the stage of the company, the firm can invest from several hundred thousand to tens of millions. The firm is geographically agonistic and looks to invest in companies based in the US, Europe, Israel, and Asia. The firm is actively seeking new investment opportunities.       

In the Life Sciences the firm is currently seeking to invest in medical devices. The firm primarily invests in novel and disruptive technologies. The firm is opportunistic in terms of the class/type and development stage of the device. Hence, the firm will consider devices at all stages: prototype, in clinic, to commercial stage. The firm is currently looking for opportunities in the hypertension, oncology, and diabetes market. Currently the firm is only looking for privately held companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

 A Venture Capital company with offices in the US and Europe is currently looking to make investments out of its fourth fund. The firm is looking to make venture stage investment generally falling in the range of $2-$6 million though investments may fall outside of this range depending upon the opportunity. The firm also reserves additional capital for follow on rounds. The firm is most interested in companies based in the US although they are also open to investing in Eastern and Northern Europe, East Asia and Australia. The firm could make as many as 5-10 investments over the next year.

The firm is primarily interested in companies developing therapeutics and to a lesser extent medical devices and research tools. Within the Therapeutics space the firm has a slight preference for companies working with platform technologies although they are open to single asset companies as well. The firm is willing to invest in small molecules, biologics, and cell and gene therapy. The firm is willing to consider opportunities from preclinical through phase III of clinical trials though most of their investments will likely be allocated to later stage companies. The firm generally only considers pre-clinical stage companies if there is a clear path to exit in a shortened timeframe. The firm is highly interested in area of RNA therapeutics, Oncology, Structural Heart and Gene Therapy and is generally less interested in CNS disorders.  For medical device companies the firms looks for technologies that are into clinical trials with a working prototype and is agnostic in terms of technology type and indication.

The firm is looking for private or publically held companies, and has special interest in companies considering going public as well as secondary’s investments. The firm prefers to invest as a member of a syndicate and does not always require a board seat following investment. The firm looks to act as a value add investor helping companies expand their networks and filling in holes in existing management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The operational and investment arm of a family office is looking to make equity investments into early stage companies and small mid-market growth companies ranging from $.5 to $1 million. The firm is very open to syndication particular with early stage deals and is capable of providing additional capital in follow on rounds when appropriate. The firm prefers to invest in companies located in the eastern United States and looks to make approximately 1-2 new investments per year.

The firm is looking for companies in the Medical Technology and Diagnostics space. Within these areas the firm is looking for 510k devices that are more technically based with a particular interest in hospital equipment and professional diagnostics. The firm is not interested in devices where the final consumer is the patient. The firm is looking to devices that improve the standard of care and is willing to invest in companies at all phases of development. The firm is generally open to all indications.

The firm looks for experienced management teams and looks to take a board seat following investment. The firm is willing to work with companies that have incomplete management teams and is looking for privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global diagnostics company is looking to form partnerships and make investments in emerging life science companies.  The firm is highly flexible about the structure of its investments, and primarily invests in North America and Europe. The firm looks to act as a long-term, highly activist investor.

The firm primarily invests in the diagnostic imaging sector, including imaging devices and agents, CT and MR technologies, and angiography.  The firm prefers to invest in companies at or near the market approval stage but is open to considering investments in earlier-stage companies.  In addition to imaging technologies, the firm is also interested in cardiology devices, and other interventional devices including delivery devices.

The firm does not provide passive financing; the firm only invests in companies developing products that the firm would eventually market and sell.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital firm based in the western United States has raised two funds is looking to make venture-stage minority equity investments. The firm is willing to both lead and co-invest in rounds and considers opportunities around the globe.

The firm is looking to invest in therapeutic development, and is primarily interested in small molecule therapeutics.  The firm may also consider investing in durable medical equipment (including hospital hardware), but in general does not invest in medical devices.  The firm only invests in novel technologies and is not interested in generics or reformulations; the firm is, however, interested in highly complex, targeted drug delivery technologies.  The firm is open to investing in any indication area, and is particularly interested in opportunities in virology and infectious diseases; oncology (particularly immuno-oncology), and cardio/metabolic diseases.  The firm invests in companies at the preclinical or early clinical stages of development.  The firm’s primary criteria is scientific novelty and does not invest in ‘me-too’ or ‘me-better’ opportunities.

The firm is a highly activist investor and prefers to manage the development process after an investment is made.  The firm therefore prefers to partner with virtual biotech companies in order to harness the firm’s relationships with CROs.  The firm prefers to invest in rounds in which a lead investor is already in place.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital division of a global medical device company is looking to make investments into early stage medical devices. The firm’s investments are highly varied in both size and structure; the structure may involve milestone payments, or may be an equity investment.  The firm is looking for companies located globally.

The firm invests in every class of medical devices.  The firm invests strategically in indication areas of interest to its parent company, including cardiovascular devices, diseases of the nervous system, and oncology devices.  The firms current portfolio includes cardiovascular and neurovascular devices, diabetes care, ophthalmic devices, diagnostic devices, surgical devices (including urological devices), aesthetics, and ENT devices.  The firm only invests in devices which have data from animal or human trials that provides evidence that the product will succeed; prototype-stage devices are not of interest.

The firm is looking to invests in medical device companies with competitive, patented technology and which are pursuing solutions to significant unmet medical needs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The Venture investment arm of a health insurance provider is looking to acquire and grow ventures with pre-money valuations from $10M-50M. The firm will consider flexible investment structures on a case-by-case basis and seeks to launch 3-5 new ventures each year. The firm invests worldwide with special interest in geographic areas with a large population of senior citizens. The group seeks technology and services that will be available in the Massachusetts market.

The firm seeks to make strategic acquisitions and investments and is solely motivated by reducing the cost of healthcare through scientific discovery and technology. Primary areas of interest include diagnostics, monitoring, preventative medical technology, automation, hardware, and software. The group will only consider technologies with health related applications.

The firm is especially interested in technologies that will impact the senior or low-income markets, including diabetes prevention and technology that can increase access to seniors. The firm seeks low risk technology; it has not invested in biotech but would consider investments in the space. The firm seeks early stage technology still in development.

The firm seeks companies with a management team experienced in one or more of the following: new ventures, healthcare development, software, mobile technology, healthcare administration, or primary care. The group seeks companies that can benefit from reaching a wide range of users through its parent company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com